Integrilin Overview and Mechanism of Action

What are the indications for Integrilin?

Which of the following are contraindications for Integrilin? (Select all that apply)

What is the mechanism of action of Integrilin?

What is the generic name of Integrilin?

What is the trade name of eptifibatide?

For Acute Coronary Syndromes, the dosage is ___ mcg/kg IV bolus over 1-2 min.

What is the route of administration for Integrilin?

What are some adverse reactions/side effects of Integrilin? (Select all that apply)

What classification does Integrilin belong to?

Integrilin Overview

Indication: Prevents the formation of blood clots, primarily used in acute coronary syndromes and during percutaneous coronary interventions.
Contraindications: Should not be used in patients with hypersensitivity, history of internal bleeding, intracranial hemorrhage or neoplasm, cerebrovascular accident (CVA), or thrombocytopenia.

Mechanism of Action

Action: Eptifibatide, the generic name for Integrilin, works by blocking the binding of fibrinogen and von Willebrand factor to the glycoprotein IIb/IIIa receptor on the surface of platelets, preventing platelet aggregation.

Administration and Dosage

Administered via: Intravenous (IV) route.
Dosage for Acute Coronary Syndromes: Initial IV bolus of 180 mcg/kg over 1-2 minutes, followed by a continuous IV infusion of 2 mcg/kg/min for up to 72 hours.
Dosage for Percutaneous Coronary Intervention: Initial IV bolus of 180 mcg/kg, followed by a continuous infusion of 2 mcg/kg/min and another IV bolus of 180 mcg/kg 10 minutes after the first.

Side Effects and Adverse Reactions

Common Adverse Reactions: May include bleeding, hypotension, and thrombocytopenia, which should be monitored closely.

Drug Classification

Classification: Integrilin is classified as an antiplatelet agent, designed to reduce clotting risk in the cardiovascular system.

This quiz covers the indications, contraindications, and mechanism of action of Integrilin, a medication used to prevent blood clots. It also details the administration route and appropriate dosages for acute coronary syndromes and percutaneous coronary interventions.